| Detected | Trial | Change |
|---|---|---|
| 2026-06-12 | NCT04494113 Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers… |
date change Primary completion pushed: 2026-06-01 -> 2026-11-30 |
| 2026-06-12 | NCT04494113 Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers… |
date change Completion pushed: 2026-06-01 -> 2026-11-30 |
| 2026-05-30 | NCT02595879 Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA… |
date change Completion pushed: 2026-04-29 -> 2027-04-29 |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT02466971 | Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy… | Advanced Vaginal Adenocarcinoma | Active, Not Recruiting |
| Phase 2 | |||
| NCT05724108 | Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted… | Metastatic Neuroendocrine Tumor | Active, Not Recruiting |
| Phase 1 | |||
| NCT06410248 | Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent… | Recurrent Glioblastoma, IDH-Wildtype | Recruiting |
| NCT06860594 | Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for… | Astrocytoma, IDH-Mutant, Grade 2 | Recruiting |
| NCT02595879 | Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA… | Advanced Cervical Adenocarcinoma | Active, Not Recruiting |
| NCT04234568 | Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based… | Metastatic Digestive System Neuroendocrine Neoplasm | Active, Not Recruiting |
| Early Phase 1 | |||
| NCT04494113 | Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers… | Endometrial Serous Adenocarcinoma | Active, Not Recruiting |